Prognosis
Pfizer To Know Covid Shot’s Efficacy Against Omicron Before Year-End
- Real-world efficacy data will be final verdict: CEO Bourla
- Pfizer expects to submit Covid drug data to FDA within days
This article is for subscribers only.
Pfizer Inc. will have data telling how well its vaccine prevents infections with the omicron variant before the end of the year, Chief Executive Officer Albert Bourla said.
The company is looking to data on the vaccine’s performance from health providers and other sources to give a clearer picture of effectiveness, Bourla said Wednesday in an interview on Bloomberg Television’s “Balance of Power With David Westin.”